SCHEMBL6239993

SCHEMBL6239993

CC(C)S(=O)(=O)NC1CCC=C1c1ccc(OCCN)cc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP2 P08253 1/20 0.34
MMP9 P14780 1/20 0.34
MMP13 P45452 1/20 0.34
HRH3 Q9Y5N1 4/20 0.34
ALDH1A1 P00352 3/20 0.33
IKBKB O14920 1/20 0.33
KDM4E B2RXH2 1/20 0.33
ITGB3 P05106 2/20 0.32
ITGA2B P08514 2/20 0.32
LMNA P02545 2/20 0.32
GAA P10253 1/20 0.32
ACACB O00763 1/20 0.32
ACACA Q13085 1/20 0.32
MEN1 O00255 1/20 0.32
KMT2A Q03164 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
LTA4H P09960 1/20 0.31
PLA2G2A P14555 1/20 0.31
TAAR1 Q96RJ0 1/20 0.31
GRIA2 P42262 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6242089 0.93 HRH3 (0.35) MMP2MMP9MMP13HRH3ALDH1A1
SCHEMBL6242856 0.88 ALDH1A1 (0.37) HRH3ALDH1A1KDM4ELMNAMEN1
SCHEMBL6242487 0.86 ALDH1A1 (0.46) HRH3ALDH1A1KDM4ELMNAMEN1
SCHEMBL6243776 0.83 GRIA2 (0.36) MMP2MMP9MMP13ALDH1A1LMNA
SCHEMBL6239997 0.83 CYP11B1 (0.36) ALDH1A1IKBKBITGB3ITGA2BLMNA
SCHEMBL6237718 0.82 FDFT1 (0.49) MMP13ACACBMEN1KMT2ALTA4H
SCHEMBL6241883 0.81 ALDH1A1 (0.38) HRH3ALDH1A1KDM4ELMNAMEN1
SCHEMBL6240540 0.80 ADAM17 (0.41) MMP2MMP9MMP13GRIA2
SCHEMBL6242553 0.80 ALDH1A1 (0.41) HRH3ALDH1A1KDM4EMEN1KMT2A
SCHEMBL6241425 0.78 GRIA4 (0.48) MMP2MMP9MMP13GRIA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1395550-B1 CYCLOALKENYLSULFONAMIDE DERIVATIVES LILLY CO ELI (US) 2005-06-29 EP disclosed
US-20040157817-A1 Cycloalkenylsulfonamide derivatives CANTELL BUDDY EUGENE (US) 2004-08-12 US disclosed
EP-1395550-A1 CYCLOALKENYLSULFONAMIDE DERIVATIVES ELI LILLY AND COMPANY (US) 2004-03-10 EP disclosed
WO-2002098847-A1 CYCLOALKENYLSULFONAMIDE DERIVATIVES ELI LILLY AND COMPANY (US) 2002-12-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040157817-A1 Cycloalkenylsulfonamide derivatives GRIN2B, GRIN2A, GRIN1 MMP2 4786/4885MMP9 4641/4885MMP13 4825/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.